Unity Biotechnology Inc

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Phase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment –

UNITY Biotechnology Provides Pipeline and Business Updates

SAN FRANCISCO, Feb.  24, 2020  (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard, chairman and chief executive officer, will present at the upcoming Cowen and Company 40th Annual Health Care Conference.

UNITY Biotechnology, Inc. to Participate in the Cowen and Company 40th Annual Health Care Conference

SAN FRANCISCO, Oct.  24, 2019  (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that two abstracts summarizing recent studies on the role of senolytic medicine in knee osteoarthritis, including a late breaking abstract on the recent Phase 1b study of UBX-0101, have been accepted for presentation at the American College of Rheumatology (ACR) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia.

UNITY Biotechnology, Inc. Announces Upcoming Scientific Presentations at ACR 2019 Annual Meeting

SAN FRANCISCO, Sept.  20, 2019  (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the upcoming Cantor Global Healthcare Conference.

UNITY Biotechnology, Inc. to Participate in the 2019 Cantor Global Healthcare Conference

Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?

Unity Biotech: Buy at the Low?

The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.

Here's Why Unity Biotechnology Dropped as Much as 20.4% Today

News for Unity Biotechnology Inc Stock (UBX)